UCB: 'tracking well' towards 2018 targets
(CercleFinance.com) - Belgian pharmaceutical group UCB confirmed its financial outlook for 2018 on Tuesday after reporting nine-month revenue that is up 3%.
Revenue for the first nine months of 2018 reached 3.4 billion euros, from 3.3 billion euros in the same period of 2017, up 6% at constant exchange rates.
In its statement, UCB said it is "tracking well" towards its full-year financial targets.
The group confirmed its forecast that revenue is set to reach 4.5-4.6 billion euros this year, with recurring EBITDA of between 1.3 billion and 1.4 billion euros, and core EPS of 4.30-4.70 euros.
UCB shares were up 0.1% at 72 euros after these numbers, while the STOXX Europe 600 Optimised Health Care index is up 0.2%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Revenue for the first nine months of 2018 reached 3.4 billion euros, from 3.3 billion euros in the same period of 2017, up 6% at constant exchange rates.
In its statement, UCB said it is "tracking well" towards its full-year financial targets.
The group confirmed its forecast that revenue is set to reach 4.5-4.6 billion euros this year, with recurring EBITDA of between 1.3 billion and 1.4 billion euros, and core EPS of 4.30-4.70 euros.
UCB shares were up 0.1% at 72 euros after these numbers, while the STOXX Europe 600 Optimised Health Care index is up 0.2%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.